The authors describe the demographics, clinical presentation, investigation, treatment, and outcomes of pediatric patients with Guillain-Barré syndrome. They identified 35 pediatric patients with Guillain-Barré syndrome presenting to a tertiary academic center over a 20-year period. The most common presenting symptoms were paresthesias (54%), weakness (49%), and myalgias (49%). Sensation was affected in 54% of patients, and hyporeflexia or areflexia was present in 94% of patients. Cranial nerve dysfunction (46%) and autonomic involvement (eg, changes in blood pressure, pulse, bowel/bladder control, or priapism; 46%) were also common. Autonomic dysfunction, cranial nerve involvement, and albuminocytological dissociation were significantly associated with a decreased time to nadir, the point when symptoms peaked (P = .015, .007, and .005, respectively). Although not statistically significant, treatment with plasmapheresis had a better success rate than intravenous immunoglobulin. The authors’ results will help to further delineate the clinical picture of Guillain-Barré syndrome in children and refine treatment strategies.
Hiraga A., Mori M., Ogawara K., et al. Differences in patterns of progression in demyelinating and axonal Guillain-Barre syndromes. Neurology. 2003;61:471-474.
2.
Sladky JTGuillain-Barre syndrome in children. J Child Neurol. 2004;19:191-200.
3.
Kuwabara S.Guillain-Barre syndrome: epidemiology, pathophysiology, and management. Drugs. 2004;64:597-610.
4.
Lee JH, Sung IY, Rew ISClinical presentation and prognosis of childhood Guillain-Barre syndrome. J Paediatr Child Health. 2008;44:449-454.
5.
Asbury AKNew concepts of Guillain-Barre syndrome. J Child Neurol. 2000;15:183-191.
6.
Nachamkin I. , Arzarte Barbosa P., Ung H., et al. Patterns of Guillain-Barre syndrome in children: results from a Mexican population. Neurology . 2007;69:1665-1671.
7.
Korinthenberg R., Monting JSNatural history and treatment effects in Guillain-Barre syndrome: a multicentre study. Arch Dis Child. 1996;74:281-287.
8.
Ropper AHThe Guillain-Barre syndrome. N Engl J Med. 1992; 326:1130-1136.
Ryan MMGuillain-Barre syndrome in childhood. J Paediatr Child Health . 2005;41:237-241.
11.
Koul RL, Alfutaisi A.Prospective study of children with Guillain-Barre syndrome. Indian J Pediatr. 2008;75:787-790.
12.
Ramirez-Zamora M., Burgos-Ganuza CR, Alas-Valle DA, et al. Guillain-Barre syndrome in the paediatric age: epidemiological, clinical, and therapeutic profile in a hospital in El Salvador. Rev Neurol. 2009;48:292-296.
13.
Korinthenberg R., Schessl J., Kirschner J.Clinical presentation and course of childhood Guillain-Barre syndrome: a prospective multicentre study. Neuropediatrics. 2007;38:10-17.
14.
Molinero MR , Varon D., Holden KR, et al. Epidemiology of childhood Guillain-Barre syndrome as a cause of acute flaccid paralysis in Honduras: 1989-1999. J Child Neurol. 2003;18: 741-747.
15.
Sarada C., Tharakan JK, Nair M.Guillain-Barre syndrome. A prospective clinical study in 25 children and comparison with adults. Ann Trop Paediatr. 1994;14:281-286.
16.
Tabarki B., Othmani K., Oubich F., et al. Guillain-Barre syndrome in children. Report of 39 cases. Tunis Med.2001;79:183-187.
Jones HRChildhood Guillain-Barre syndrome: clinical presentation, diagnosis, and therapy . J Child Neurol. 1996;11:4-12.
19.
Singh NK, Jaiswal AK, Misra S., Srivastava PKAssessment of autonomic dysfunction in Guillain-Barre syndrome and its prognostic implications. Acta Neurol Scand. 1987;75:101-105.
20.
van Doorn PA , Ruts L., Jacobs BCClinical features, pathogenesis, and treatment of Guillain-Barre syndrome. Lancet Neurol. 2008;7:939-950.
21.
Zochodne DWAutonomic involvement in Guillain-Barre syndrome: a review. Muscle Nerve. 1994;17:1145-1155.
22.
Flachenecker P.Autonomic dysfunction in Guillain-Barre syndrome and multiple sclerosis. J Neurol.2007;254:1196-101.
23.
Hughes RA, Wijdicks EF, Benson E., et al. Supportive care for patients with Guillain-Barre syndrome. Arch Neurol. 2005;62: 1194-1198.
24.
Ho TW, Hsieh ST, Nachamkin I., et al. Motor nerve terminal degeneration provides a potential mechanism for rapid recovery in acute motor axonal neuropathy after Campylobacter infection . Neurology. 1997;48:717-724.
25.
Visser LH, van der Meche FG, Meulstee J., et al. Cytomegalovirus infection and Guillain-Barre syndrome: the clinical, electrophysiologic, and prognostic features. Dutch Guillain-Barre Study Group . Neurology. 1996;47:668-673.
26.
Olive JM, Castillo C., Castro RG, de Quadros CAEpidemiologic study of Guillain-Barre syndrome in children <15 years of age in Latin America. J Infect Dis. 1997;175:S160-S164.
27.
Ravn H.The Landry-Guillain-Barre syndrome. A survey and a clinical report of 127 cases. Acta Neurol Scand.1967;43:1-64.
28.
Winer JB, Hughes RA, Osmond C.A prospective study of acute idiopathic neuropathy. I. Clinical features and their prognostic value. J Neurol Neurosurg Psychiatry.1988;51:605-612.
29.
Anonymous Appropriate number of plasma exchanges in Guillain-Barre syndrome. The French Cooperative Group on Plasma Exchange in Guillain-Barre Syndrome. Ann Neurol. 1997;41:298-306.
30.
Chio A., Cocito D., Leone M., et al. Guillain-Barre syndrome: a prospective, population-based incidence and outcome survey. Neurology. 2003;60:1146-1150.
31.
Cheng Q., Wang DS, Jiang GX, et al. Prospective study of clinical epidemiology of Guillain-Barre syndrome in Harbin, China. J Neurol Sci. 2003 ;215:63-69.
32.
Ruts L., van Koningsveld R., van Doorn PADistinguishing acute-onset CIDP from Guillain-Barre syndrome with treatment related fluctuations. Neurology. 2005;65:138-140.
33.
Anonymous.The prognosis and main prognostic indicators of Guillain-Barre syndrome. A multicentre prospective study of 297 patients. The Italian Guillain-Barre Study Group. Brain.1996;119:2053-2061.
34.
Vedeler CA, Wik E., Nyland H.The long-term prognosis of Guillain-Barre syndrome. Evaluation of prognostic factors including plasma exchange. Acta Neurol Scand.1997;95:298-302.
35.
Lawn ND, Fletcher DD, Henderson RD, et al. Anticipating mechanical ventilation in Guillain-Barre syndrome . Arch Neurol. 2001;58:893-898.
36.
Hiraga A., Kuwabara S.Early prediction of prognosis in Guillain-Barre syndrome. Lancet Neurol. 2007;6:572-573.
37.
Souayah N., Nasar A., Suri MF, Qureshi AIGuillain-Barre syndrome after vaccination in United States: data from the Centers for Disease Control and Prevention/Food and Drug Administration Vaccine Adverse Event Reporting System (1990-2005). J Clin Neuromuscul Dis. 2009;11:1-6.
38.
Schonberger LB, Bregman DJ, Sullivan-Bolyai JZ, et al. Guillain-Barre syndrome following vaccination in the National Influenza Immunization Program, United States, 1976-1977. Am J Epidemiol. 1979;110:105-123.
39.
Langmuir AD , Bregman DJ, Kurland LT, et al. An epidemiologic and clinical evaluation of Guillain-Barre syndrome reported in association with the administration of swine influenza vaccines. Am J Epidemiol. 1984;119:841-879.
40.
Breman JG, Hayner NSGuillain-Barre syndrome and its relationship to swine influenza vaccination in Michigan, 1976-1977. Am J Epidemiol. 1984 ;119:880-889.
41.
Safranek TJ , Lawrence DN, Kurland LT, et al. Reassessment of the association between Guillain-Barre syndrome and receipt of swine influenza vaccine in 1976-1977: results of a 2-state studyExpert Neurology Group. Am J Epidemiol.1991;133:940-951 .
42.
Centers for Disease Control and Prevention.Summary of 2009 Monovalent H1N1 Influenza Vaccine Data-Vaccine Adverse Event Reporting System Data through December 4, 2009. Centers for Disease Control and Prevention, US Dept of Health and Human Services ; 2009.
43.
Aicardi J. In: Diseases of the Nervous System in Childhood. 2nd ed. London: Mac Keith Press; 1998.
44.
Hadden RD, Cornblath DR, Hughes RA, et al. Electrophysiological classification of Guillain-Barre syndrome: clinical associations and outcome. Plasma Exchange/Sandoglobulin Guillain-Barre Syndrome Trial GroupAnn Neurol.1998;44:780-788.
45.
Alam TA, Chaudhry V., Cornblath DRElectrophysiological studies in the Guillain-Barre syndrome: distinguishing subtypes by published criteria. Muscle Nerve. 1998;21:1275-1279.
46.
Brown WF, Feasby TEConduction block and denervation in Guillain-Barre polyneuropathy. Brain. 1984;107:219-239.
47.
Gordon PH, Wilbourn AJEarly electrodiagnostic findings in Guillain-Barre syndrome. Arch Neurol. 2001;58:913-917.
48.
Spaans F., Vredeveld JW, Morre HH, et al. Dysfunction at the motor end-plate and axon membrane in Guillain-Barre syndrome: a single-fiber EMG study. Muscle Nerve. 2003;27:426-434.
49.
Nagasawa K. , Kuwabara S., Misawa S., et al. Electrophysiological subtypes and prognosis of childhood Guillain-Barre syndrome in Japan. Muscle Nerve. 2006;33:766-770.
50.
Byun WM, Park WK, Park BH, et al. Guillain-Barre syndrome: MR imaging findings of the spine in eight patients. Radiology. 1998;208:137-141.
Coskun A., Kumandas S., Pac A., et al. Childhood Guillain-Barre syndrome. MR imaging in diagnosis and follow-up. Acta Radiol.2003;44:230-235.
53.
Rasul CH, Das PL, Alam S., et al. Clinical profile of acute flaccid paralysis. Med J Malaysia. 2002;57:61-65.
54.
Bradshaw DY , Jones HR, Jr.Guillain-Barre syndrome in children: clinical course, electrodiagnosis, and prognosis. Muscle Nerve . 1992;15:500-506.
55.
Jones HR, De Vivo DC, Darras BTNeuromuscular Disorders of Infancy, Childhood, and Adolescence: A Clinician’s Approach. Boston, MA: Butterworth-Heinemann ; 2003.
56.
Hughes RAPlasma exchange versus intravenous immunoglobulin for Guillain-Barre syndrome . Ther Apher. 1997;1:129-130.
